Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5540)	1/24/2002 7:30:19 PM
From: seminole	Respond to of 52153

Peter The recent price move seems to be from the Wachovia conference on January 16. MGI's home page has a recording of the presentation with the slides. Iro is on track for completion of Phase III in the third quarter 2002. I would think they will lead with this data at ASCO 2003. MG98, the methyltransferase stuff, is located at slide 24 of the presentation. They began Phase II for Head and Neck in Nov. 2000, so I expect a presentation at ASCO this year. But my guess is that Palosetron is going to move the stock this year and I will have to wait another year on IRO. (PALO is a 5-HT antagonist targeting the $1 billion market for nausea and vomiting.) The Phase III trial is complete for PALO and I expect the data from Phase II to be presented at ASCO. But if the data backs up their claim of a much longer half life (40 hours compared to 5-7 for current 5-HT antagonist drugs), the stock price should advance before we se the Phase III data.